A phase Ib/II study of cancer stem cell inhibitor BBI608 administered with panitumumab in KRAS wild-type (wt) patients (pts) with metastatic colorectal cancer (mCRC) following progression on anti-EGFR therapy.
Kristen K. Ciombor(The Ohio State University), Tanios Bekaii‐Saab(WinnMed), Joleen M. Hubbard(Rutgers, The State University of New Jersey), Wei Li(University of California, Irvine), Divya Manoharan(Boston Biomedical (United States)), Peter J. O’Dwyer(University of Pennsylvania), Chiang Li(Boston Biomedical (United States)), Alexander I. Spira(Virginia Cancer Specialists), Youzhi Li(Boston Biomedical (United States)), Axel Grothey(Campbell Clinic), Carlos Becerra(Texas Oncology), William J. Edenfield(Prisma Health), Tim Larson(New York University), Laura Borodyansky(Boston Biomedical (United States))
Cited by 6
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k